Pressures on US industry go beyond current price squeeze

As well as ongoing price erosion in the US, generics and biosimilars firms must fight back against brand industry attempts to thwart competition as well as regulatory obstacles looming on the horizon, AAM president and chief executive officer Chip Davis told Generics bulletin managing editor Dave Wallace.